Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TEV-749
- Development stage
- Phase 3
- Lead developer
- Teva Pharmaceutical Industries
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
TEV-749 is an investigational once-monthly subcutaneous long-acting injectable (LAI) formulation of the second-generation (atypical) antipsychotic olanzapine. Developed using Medincell’s proprietary SteadyTeq copolymer technology, it provides a controlled and steady release of olanzapine over a month. The drug is designed to improve adherence in adults with schizophrenia by offering a convenient monthly injection as an alternative to daily oral dosing or intramuscular LAIs that carry risks such as post-injection delirium/sedation syndrome (PDSS). In Phase 3 clinical trials (SOLARIS), TEV-749 demonstrated significant improvements in schizophrenia symptoms—measured by the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression-Severity scale (CGI-S), and Personal and Social Performance scale (PSP)—with no reported cases of PDSS. The safety profile was consistent with other approved formulations of olanzapine[1][2][3][4][5][6][7][8].
- Other names
- olanzapine extended-release injectable suspensionsubcutaneous olanzapine LAISteadyTeq olanzapine
02
Targets
DRD2 (Dopamine D2 Receptor)HTR2A (Serotonin receptor 5-HT2A)
Beyond the preview
Go deeper on TEV-749.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TEV-749.